The Dexamethasone Implant industry trends over the past 18 months reflect dynamic advancements driven by strategic collaborations and regulatory shifts. In 2024, Allergan partnered with Ocular Therapeutix to co-develop a next-generation extended-release dexamethasone implant targeting posterior uveitis, leveraging Ocular’s proprietary drug delivery platform to enhance therapeutic efficacy. Meanwhile, Bausch Health launched DEXTENZA™ Plus in late 2023, a novel implant with a 6-month duration, addressing unmet needs in chronic ocular inflammation management. Regulatory updates in 2024, including the FDA’s revised guidelines for long-acting corticosteroid safety profiling, have prompted manufacturers to prioritize real-world evidence collection during clinical trials. Consumer demand has shifted toward minimally invasive, single-dose solutions, with telemedicine integration for remote patient monitoring driving adoption in post-surgical care. Notably, Santen Pharmaceutical expanded its Asian footprint in 2023 through a $150 million facility upgrade, while RetinaTech secured $30 million in Series B funding to accelerate its AI-assisted implant navigation system. These developments underscore a market poised for innovation, with cost containment pressures and digital health convergence shaping future growth trajectories.
